Comparative Pharmacology
Head-to-head clinical analysis: IMPAVIDO versus PENTAMIDINE ISETHIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPAVIDO versus PENTAMIDINE ISETHIONATE.
IMPAVIDO vs PENTAMIDINE ISETHIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miltefosine, the active ingredient in IMPAVIDO, is an alkylphosphocholine with antileishmanial activity. It interacts with cell membrane phospholipids, inhibits cytochrome c oxidase, and induces apoptosis-like cell death in Leishmania parasites. It also modulates host immune responses.
Pentamidine isethionate is a synthetic aromatic diamidine that interferes with protozoal DNA replication, transcription, and RNA processing. Its exact mechanism is unclear but may involve inhibition of dihydrofolate reductase, interference with polyamine synthesis, and binding to kinetoplast DNA.
60 mg/kg body weight per day (2.5 mg/kg per hour) by intravenous infusion over 6 hours, up to a maximum of 150 mg/day, for 21 days.
Treatment of Pneumocystis jirovecii pneumonia (PCP): 4 mg/kg IV once daily for 21 days. Chemoprophylaxis of PCP: 300 mg inhalation via nebulizer every 4 weeks, or 4 mg/kg IV every 2-4 weeks. Treatment of leishmaniasis: 2-4 mg/kg IM or IV once daily or every other day for 14-30 doses.
None Documented
None Documented
Terminal elimination half-life is approximately 16-21 days in adults; may be longer in severe hepatic impairment.
Terminal elimination half-life is 18-24 hours in patients with normal renal function; prolongs to >48 hours in renal impairment, necessitating dose adjustment.
Primarily renal (over 90% as unchanged drug); fecal excretion is minimal (<5%).
Renal excretion accounts for approximately 60-70% of elimination, primarily as unchanged drug. Biliary/fecal elimination constitutes 10-20%, with the remainder undergoing metabolic clearance.
Category C
Category A/B
Antiprotozoal
Antiprotozoal